Zusammenfassung
Das Lungenödem ist definiert als Vermehrung der extravasalen Flüssigkeit im Interstitium allein oder auch zusätzlich in den Alveolen der Lunge, unabhängig von der zugrundeliegenden Ätiologie. Es entsteht dann, wenn mehr Flüssigkeit aus dem Blut in das Interstitium und in die Alveolen austritt, als aus diesem Bereich in das Blut und in die lymphatischen Gefäße rückresorbiert wird (Harris u. Heath 1986).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Literatur
Connors AF, Speroff T, Dawson NV et al. (1996) The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. JAMA 276: 889–897
Fishman AP (1988) Pulmonary edema. In: Fishman AP (ed) Pulmonary diseases and disorders, 2nd edn. McGraw-Hill, New York, pp 919–928
Guyatt G (1991) A randomized control trial of right heart cathetarization in critically ill patients. Ontario intensive care study group. J Intensive Care Med 6: 91–951
Hubmayr RD, Abel MD, Rehder K (1990) Physiologic approach to mechanical ventilation. Crit Care Med 18: 103–114
Irwin RS (1991) Mechanical ventilation. Part I: Initiation (Chap IV, p 54 ). In: Rippe JM et al. (eds) Intensive care medicine, 2nd edn. Little, Brown, Boston
Tobbin MJ, Dantzker DR (1991) Mechanical ventilation and weaning (Chap 11). In: Dantzker DR (ed) Cardiopulmonary critical care, 2nd edn. Saunders, Philadelphia
Literatur zu Sektion V Kap.31
ACC/AHA Task Force Report (1995) Guidelines fort the Evaluation and Management of Heart Failure. Circulation 92: 2764–2784
Acsadi GA, Jiao S, Jani A, Duke D, Williams CW, Wolff JA (1991) Direct gene transfer and expression into rat heart in vivo. New Biologist 3: 71–81
Acute Infarction Ramipril Efficacy (AIRE) Study Investigators (1993) Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. I,ancet 342: 821–828
Admiral PJJ, Derkx-Admiraal FHM, Jan Danser AH et al. (199o) Metabolism and production of angiotensin I in different vascular beds in subjects with hypertension. Hypertension 15: 44–52
Aguirre FV, Pearson AC, Lewen MK, McCluskey M, Labovitz AJ • (1989) Usefulness of doppler echocardiography in the diagnosis of congestive heart failure. Am J Cardiol 63: 1098–1102
Akera T, Brody TM (1978) The Role of Na+/K+-ATPase in the inotropic action of digitalis. Pharmacol Rev 29: 187–220
Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA (1998) Antiplatelet agents and survival: A cohort analysis from the studies of left ventricular dysfunction ( SOLVD) trial. J Am Coll Cardiol 31: 419–425
Allen DG, Jewell BR, Murray JW (1974) The contribution of activation processes to the length-tension relation of cardiac muscle. Nature 248: 606–607
Allen DG, Kentish JG (1985) The cellular basis of the length-tension relation in cardiac muscle. J Mol Cell Cardio117: 821–840
Amery A, Brixco O, Clement D et al. (1985) Mortality and morbidity results from the european working party on high blood pressure in the elderly trial. Lancet 1: 1349–1351
Amiodarone Trials Meta–Analysis Investigators (1997) Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta–analysis of individual data from 6500 patients in radomised trials. Lancet 350: 14–17–1424
Anand IS, Ferrari R, Kalra GS, Wahi PL, Poole-Wilson PA, Harris PC (1989) Edema of cardiac origin. Circulation 80: 299–305
Anderson PAW, Malouf NN, Oakeley AE, Pagani ED, Allen PD (1991) Troponin T isoform expression in humans. A comparison among normal and failing adult heart, fetal heart, and adult and fetal skeletal muscle. Circ Res 69: 1226–1233
Anonymus (1991) Calcium antagonist caution. Lancet 337: 885–886
Anversa P, Hiler B, Ricci R, Guideri G, Olivetti G (1986) Myocyte loss and myocyte hypertrophy in the aging rat heart. J Am Coll Cardiol 8: 1441–1448
Arai M, Alpert NR, MacLennan DH, Barton P, Periasamy M (1993) Alterations in sarcoplasmic reticulum gene expression in human heart failure. A possible mechanism for alterations in systolic and diastolic properties of the failing myocardium. Circ Res 72: 463–469
Arai M, Matsu H, Periasamy M (1994) Sarcoplasmic reticulum gene expression in cardiac hypertrophy and heart failure. Circ Res 74: 555–564
Arai M, Otsu K, MacLennan DH, Periasamy M (1992) Regulation of sarcoplasmic reticulum gene expression during cardiac and skeletal muscle development. Am J Physiol 262: C614 - C62o
Arnold SB, Bird RC, Meister W et al. (1980) Long-term digitalis therapy improves left ventricular function in heart failure. N Engl J Med 303: 1443–1449
Aufiero TX, Reddy RC, Magovern JA et al. (1995) Alternatives to human heart replacement. Curr Opin Cardiol lo: 218–222 Bairn DS (1985) Effects of amrinone on myocardial energetics in severe heart failure. Am J Cardiol 56: 16B - 21B
Barcenas-Ruiz L, Beuckelmann DJ, Wier WG (1987) Sodium-calcium exchange in heart: currents and changes in [Ca2+1. Science 238: 1720–1722
Bayliss J, Norell M, Capena-Anson R et al. (1987a) Untreated heart failure: Clinical and neuroendocrine effects of introducing diuretics. Br Heart J 57: 17–21
Bayliss J, Thomas L, Poole-Wilson P (1987b) Acute hemodynamic and neuroendocrine effects of dopexamine, a new vasodilator for the treatment of heart failure: comparison with dobutamine, captopril, and nitrate. J Cardiovasc Pharmacol 9: 551–559
Benotti JR, Grossman W, Braunwald E, Davalos DD, Alousi AA (1978) Hemodynamic assessment of amrinone–a new inotropic agent. N Engl J Med 299: 1373–1379
Benotti JR, McCue JE, Alpert JS (1985) Comparative vasoactive therapy for heart failure. Am J Cardiol 56: 19B - 24B
Beuckelmann DJ, Erdmann E (1991) Herzinsuffizienz bei dilatati-ver Kardiomyopathie–Eine Störung der Calciumhomöostase. Dtsch Med Wochenschr 116: 504–508
Beuckelmann DJ, Näbauer M, Erdmann E (1991) Characteristics of calcium-current in isolated human ventricular myocytes from patients with terminal heart failure. J Mol Cell Cardiol 23: 929–937
Beuckelmann DJ, Näbauer M, Erdmann E (1992) Intracellular calcium handling in ventricular myocytes from patients with terminal heart failure. Circulation 85: 1046–1055
Beuckelmann DJ, Näbauer M, Erdmann E (1993) Alterations of K+-currents in isolated human ventricular myocytes from patient with terminal heart failure. Circ Res 73: 379–385
Beuckelmann DJ, Wier WG (1989) Sodium-calcium exchange in guinea-pig cardiac cells: exchange current and intracellular calcium. J Physiol (London) 499–520
Binkley PF, Nunziata E, Haas GJ, Nelson SD, Cody RJ (1991) Parasympathetic withdrawal is an integral component of autonomic imbalance in congestive heart failure: demonstration in human subjects and verification in a paced canine model of ventricular failure. J Am Coll Cardiol 18: 464–472
Birnbaumer L (1987) Which G protein subunits are the active mediators in signal transduction? Trends Pharmacol Sci 8: 209–211
Blech JJF, Budges AB, Scott N, Chopra M (1991) Oxygen free radicals and congestive heart failure. Br Heart J 65: 245–248
Boheler KR, Carrier L, De la Bastie D, Allen PD, Komajda M, Mercadier JJ, Schwartz K (1991) Skeletal actin m-RNA increases in the human heart during ontogenic development and is the major isoform of control and failing adult hearts. J Clin Invest 88: 323–330
Boheler KR, Chassagne C, Martin X, Wisnewsky C, Schwartz K (1992) Cardiac expressions of a-and 13-myosin heavy chains and sarcomeric a-actins are regulated through transcriptional mechanism. Results from nuclear run-on assays in isolated rat cardiac nuclei. J Biol Chem 267: 12979–12985
Boheler KR, Schwartz K (1992) Gene expression in cardiac hypertrophy. Trends Cardiovasc Med 2: 176–182
Böhm M, Beuckelmann D, Brown L et al. (1988) Reduction of ß-adrenoceptor density and evaluation of positive inotropic responses in isolated, diseased human myocardium. Eur Heart J 9: 844–852
Böhm M, Diet F, Feiler G, Kemkes B, Kreuzer E, Weinhold C, Erdmann E (199oa) Subsentive of the failing human heart to isoprenaline and milrinone is related to 3-adrenoceptor downregulation. J Cardiovasc Pharmacol 12: 726–732
Böhm M, Dorner H, Htun P, Lensche H, Platt D, Erdmann E (1994) Effects of exercise on myocardial adenylate cyclase and Gi-expression in senescence. Am J Physiol 264: 805–814
Böhm M, Gierschik P, Jakobs K-H, Pieske B, Schnabel P, Ungerer M, Erdmann E (199ob) Increase of Gia in human hearts with dilated but not ischemic cardiomyopathy. Circulation 82: 1249–1265
Böhm M, Morano I, Pieske B, Rüegg JC, Wankerl M, Zimmermann R, Erdmann E (1991) Contribution of cAMP-Phosphodiesterase inhibition and sensitization of the contractile proteins for calcium to the inotropic effect of pimobendan in the failing human myocardium. Circ Res 68: 698–701
Böhm M, Pieske P, Schnabel P, Schwinger R, Kemkes B, Klövekorn WP, Erdmann E (1989) Reduced effects of dopexamine on force of contraction in the failing human heart despite preserved I2 adrenoceptor subpopulation. J Cardiovasc Pharmacol 14: 549–559
Böhm M, Reuschel-Janetschek E, Erdmann E (199oc) Lack of sustained hemodynamic effects of the 3 adrenoceptor agonist dopexamine in end-stage congestive heart failure. Am J Cardiol 65: 395–396
Böhm M, Schwinger RHG, Erdmann E (199od) Different cardiodepressant potency of various calcium antagonists in human myocardium. Am J Cardiol 66: 1039–1041
Böhm M, Zolk O, Flesch M, Schiffer F, Schnabel P, Stasch JP, Knorr A (1998) Effects of angiotensin II type 1 receptor blockade and angiotensin-converting enzyme inhibition on cardiac ß-adrenergic signal transduction. Hypertension 31: 747–754
Bolte HD, Luderitz B, Erdmann E (1971) Beziehungen zwischen Elektrolytstörungen and Glykosidwirkungen. In: Kluthe R (Hrsg) Medikamentöse Therapie bei Nierenerkrankungen. Thieme, Stuttgart, S 138
Bonow RO, Udelson JE (1992) Left ventricular diastolic dysfunc- tion as a cause of heart failure. Ann Intern Med 117: 502–510
Borow KM, Green LIT Grossman W, Braunwald E (1982) Left ventricular end-systolic stress-shortening and stress-length relations in humans. Am J Cardiol 50: 1301–1311
Bouvagnet P, Mairhofer H, Leger JO (1989) Distribution of pattern of myosin in normal diseased human ventricular myocardium. Basic Res Cardiol 84: 91–98
Bowditch HP (1871) Über die Eigentümlichkeit der Reizbarkeit, welche die Muskelfasern des Herzens zeigen. Ber Sächs Ges (Akad) Wis 652–689
Brillantes AM, Allen P, Takahasi T, Izumo S, Marks AR (1992) Differences in cardiac calcium release channel (ryanodine receptor) expression in myocardium from patients with endstage heart failure caused by ischemic vs. dilated cardiomyopathy. Circ Res 71: 18–26
Bristow MR, Anderson FL, Port JD et al. (199,) Differences in ß-adrenergic neuroeffector mechanisms in ischemic vs. idiopathic dilated cardiomyopathy. Circulation 84: 1024–1039
Bristow MR, Gilbert Em, Abraham WT et al., for the MOCHAInvestgators (1996) Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 94: 2807_2816
Bristow MR, Ginsburg R, Minobe W et al. (1982) Decreased catecholamine sensitivity and ß-adrenergic-receptor density in failing human hearts. N Engl J Med 307: 205–211
Bristow MR, Ginsburg R, Umans V et al. (1986) ß,- and 02-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective 31-receptor down-regulation in heart failure. Circ Res 59: 297–309
Bristow MR, Hershberger RE, Port JD, Minobe W, Rasmssen R (1989) Or and 132-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol Pharmacol 35: 295–303
Brodde OE (1995) ß,- and 01-adrenoceptors in the human heart properties, function, and alterations in chronic heart failure. Pharmacol Rev 43: 203–242
Brodde 0E, OHara N, Zerkowski HR, Rohm N (1984) Human cardiac adrenoceptors both ß,- and 0,-adrenoceptors are functionally coupled to the adenylate cyclase in right atrium. J Cardiovasc Pharmacol 6: 1184–1191
Brodde 0E, Zerkowski HR, Doetsch N, Motomura S, Khamssi M, Michel MC (1989) Myocardial ß-adrenoceptor changes in heart failure: concomitant reduction in ß,- and 32-adrenoceptor function related to the degree of heart failure in patients with mitral valve disease. J Am Coll Cardiol 14: 323–331
Brömme HJ, Holtz J (1996) Apoptosis in the heart: when and why? Mol Cell Biochem 163 /164: 261–275
Brown JJ, Davies DL, Johnson VW (1970) Renin relationships in congestive heart failure, treated and untreated. Am Heart J 80: 329–336
Brown LA, Harding SE (1992) The effect of pertussis toxin on ß,-adrenoceptor responses in isolated cardiac myocytes from noreadrenaline-treated guinea-pigs and patients with cardiac failure. Br J Pharmacol 106: 115–122
Brown RA, Dixon J, Farmer JB et al. (1985) Dopexamine: a novel agonist at peripheral dopamine receptors and 132-adrenoceptors. Br J Pharmacol 85: 599–608
Brunkhorst D, Leyen H von der, Meyer W et al. (1989) Relation of positive inotropic and chronotropic effects of pimobendan, UD-CG 212 Cl, milrinone and other phosphodiesterase inhibitors to phosphodiesterase III inhibition in guinea pig heart. Naunyn Schmiedebergs Arch Pharmacol 339: 575–583
Buckley NM, Penefsky ZJ, Litwak RS (1972) Comparative force-frequency-relationship in human and other mammalian ventricular myocardium. Pflugers Arch 332: 259–270
Burkart F, Erdmann E, Hanrath P et al. (1993) Therapie der chronischen Herzinsuffizienz. Z Kardiol 82: zoo-206
Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D, with the technical assistance of Jordi H (1990) Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel antiarrhythmic study of infarct survical ( BASIS ). J Am Coll Cardiol 16: 1711–1718
Butcher RW, Sutherland EW (1962) Adenosine 3`,5`-phosphate in biological materials. Purification and properties enzyme to characterize adenosine 3`,5`-phosphate in human urine. J Biol Chem 237: 1244–1249
Capasso JM, Malhotra A, Remily RM, Scheuer J, Sonnenblick EH (1983) Effects of age on mechanical and electrical performance of rat myocardium. Am J Physiol 245 (Heart Circ Physiol 14): H72 - H81
Captopril Multicenter Research Group (1983) A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol 2: 755–763
Cardiac Arrhythmia Suppression Trial II Investigators (1992) Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 327: 227–233
Cazeau S, Ritter P, Bakdach S, Lazarus A, Limousin M, Henao L, Mundler O, Daubert JC, Mugica J (1994) Four chamber pacing in dilated Cardiomyopathy. PACE 17: 1974–1979
Chatterjee K, Ports TA, Brundage BH, Massie B, Holly AN, Parmley WW (1980) Oral hydralazine in chronic heart failure: sustained beneficial hemodynamic effects. Ann Intern Med 92: 600–604
Chen FY, Adams DH, Aranki SF, Collin JJ, Couper GS, Rizzo RJ, Cohn LH (1998) Mitral valve repair in cardiomyopathy. Circulation 98: II-1224-((-127
Cheng W, Li B, Kajstura J, Li P, Wolin MS, Sonnenblick EH, Hintze TH, Olivetti G, Anversa P (1995) Stretch-induced programmed myocyte cell death. J Clin Invest 96: 2247–2259
Chidsey CA, Braunwald E, Morrow AG (1965) Catechol-amine excretion and cardiac stores of norepinephrine in congestive heart failure. Am J Med 39: 442–451
Chien KR, Knowlton KU (1989) Cardiovascular molecular biology. Introduction to the series. Circulation So: 219–233
CIBIS Investigators and Committees (1994) A randomized trial of 3-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 9o: 1765–1773
CIBIS-II Investigators and Committees (1999) The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 353: 9–13
Cigola E, Kajstura J, Li B, Meggs LG, Anversa P (1997) Angiotensin II activates programmed myocyte cell death in vitro. Exp Cell Res 231: 363–371
Cittadini A, Grossmann DJ, Napoli R, Katz SE, Strömer H, Smith RJ, Clark R, Morgan JP, Douglas PS (1997) Growth hormone attenuates early ventricular remodeling and improves cardiac function in rats with large myocardial infarction. J Am Coll Cardiol 29: 1109–1116
Cody RJ, Atlas SA, Laragh JH et al. (1986) Atrial natriuretic factor in normal subjects and heart failure patients: plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest 78: 1362–1374
Cohn IN (1989) The sympathetic nervous system in heart failure. J Cardiovasc Pharmacol 14 (Suppl 5): 57–61
Cohn JN (1990) Abnormalities of peripheral nervous system control in congestive heart failure. Circulation 82 (Suppl I): 159–167
Cohn JN, Archibald DG, Ziesche S et al. (1986) Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med 314: 1547–1552
Cohn JN, Goldstein SO, Greenberg BH et al. (1998) A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med 339 (25): 1810–1816
Cohn JN, Johnson G, Ziesche S et al. (1991) Comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325: 303–310
Cohn JN, Levine TB, Olivari MT et al. (1984) Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311: 819–823
Cohn JN, Ziesche S, Smith R et al. (1997) Effect of the calcium antagonist felodipine as supplementary vasodilator therapie in patients with chronic heart failure treated with enalapril. Circulation 96: 856–863
Colucci WS, Alexander RW, Williams GH et al. (1981) Decreased lymphocyte 13-adrenergic receptor density in patients with heart failure and tolerance to the 13-adrenergic agonist pirbuterol. N Engl J Med 305: 185–190
Consensus Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316: 1429–1435
Conway MA, Allis J, Ouwerkerk R et al. (1991) Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P-magnetic resonance spectroscopy. Lancet 38: 973–976
Corbalân R, Jalil J, Chamorro G, Casanegra P, Valenzuela P (1990) Effects of captopril vs. milrinone therapy in modulating the adrenergic nervous system response to exercise in congestive heart failure. Am J Cardiol 65: 644–649
Courville C, Mason VR (1938) The heart in acromegaly. Arch Intern Med 61: 704–713
Cowburn PJ, Cleland JGF, McArthur JD et al. (1998) Short-term haemodynamic effects of BQ-123, a selective endothelin ETA-receptor antagonist, in chronic heart failure. Lancet 352: 201–202
Crozier I, Ikram H, Awan N et al. (1995) Losartan in heart failure, hemodynamic effects and tolerability. Circulation 91: 691–697
Cuneo RC, Wilmshurst P, Lowy C, McGauley G, Sönksen PH (1989) Cardiac failure responding to growth hormone. Lancet: 838–839
Danielsen W, Leyen H von der, Meyer W et al. (1989) Basal and isoprenaline-stimulated cAMP content in failing vs. nonfailing human cardiac preparations. J Cardiovasc Pharmacol 14: 171–173
Danish Study Group on Verapamil after myocardial infarction (1990) Secondary prevention with verapamil after myocardial infarction. Am J Cadiol 66: 331–401
DasGupta P, Broadhurst P, Lahiri A (1991) The effects of intravenosus carvedilol, a new multiple action vasodilatory ß-blocker, in congestive heart failure. J Cardiovasc Pharmacol 18 (Suppl 4): 12–16
De la Bastie D, Levitsky D, Rappaport L et al. (1990) Function of the sarcoplasmic reticulum and expression of its Cat+-ATPasegene in pressure overload-induced cardiac hypertrophy in the rat. Circ Res 66: 554–564
Demopoulos L,Yeh M, Gentilucci M et al. (1997) Nonselective 13-adrenergic blockade with carvedilol does not hinder the benefits of exercise training in patients with congestive heart failure. Circulation 95: 1764–1767
DiBianco R, Shabetai R, Kostuk W et al. (1989) A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 320: 677–683
Dibner-Dunlap ME, Thames MD (1990) Abnormalities of baroreflex control in heart failure. Heart Failure 6: 12–16
Dickstein K, Chang P, Willenheimer R et al. (1995) Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol 26: 438–445
Dies F, Krell MJ, Whitlow P et al. (1986) Intermittend dobutamine in ambulatory outpatients with chronic cardiac failure. Circulation (Suppl II): II - 138
Dies F, Krell MJ, Whitlow P et al. (1986) Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure. Circulation 74 (Suppl II): II - 138
Digitalis Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336: 525–533
Digitalis Investigation Group (1998) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336: 525–533
Docherty JR (1990) Cardiovascular responses in ageing: A Review. Pharmacol Rev 42: 103–125
Doval HC, Nul DR, Grancelli HO et al., for Grupo de la Sobrevida en al insuficiencia Cardiaca en Argentina (GESiCA) (1994) Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 344: 493–498
Drexler H (1993) Der periphere Kreislauf bei chronischer Herzinsuffizienz. Internist 34: 961–964
Drexler H, Lu W (1992) Endothelial dysfunction of hindquarter resistance vessels in experimental heart failure. Am J Physiol 262: H164o-H1645
Dubois-Randé, Merlet P, Roudot F et al. (1992) 3-adrenergic contractile reserve as a predictor of clinical outcome in patients with idiopathic dilated cardiomyopathy. Am Heart J 124: 679–685
Duerr RL, Huang S, Miraliakbar HR, Clark R, Chien KR, Ross Jr J (1995) Insulin-like growth factor-I enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. J Clin Invest 950: 6190–6270
Duerr RL, Mc Kirnan D, Gim RD, Clark RG, Chien KR, Ross Jr J (1996) Cardiovascular effects of insulin-like growth facotr-I and growth hormone in chronic left ventricular failure in the rat. Circulation 93: 2188–2196
Dupuis J, Goresky CA, Fournier A (1996) Pulmonary clearance of circulationg endothelin-1 in dogs in vivo: Exclusive role of ET(B) receptors. J Appl Physiol 81: 1510–1515
Düsing R (1986) Diuretika. Pharmakologie and therapeutischer Einsatz. Wiss. Verlagsges. Stuttgart, S 1–108
Dyckner T, Wester PO (1985) Skeletal muscle magnesium and potassium determinations: correlation with lymphocyte contents of magnesium and potassium. J Am Coll Nutr 4: 619–625
Dzau V, Colucci W, Hollenberg N, Williams G (1981) Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 63: 645–656
Dzau VJ, Burt DW, Pratt RE (1988) Molecular biiiology of the reninangiotensin system. Am J Physiol 255: 563–573
Dzau VJ, Gibbons GH (1987) Autocrine-paracrine mechanisms of vascular myocytes in hypertension. Am J Cardiol 60: 991–996
Dzau VJ, Hollenberg NK (1984) Renal response to captopril in severe heart failure: Role of furosemide in natriuresis and reversal of hyponatremia. Ann Int Med loo: 777–782
Dzau VJ, Packer M, Lilly LS et al. (1984) Prostaglandins in severe heart failure: relation to activation of the renin-angiotensin system and hyponatremia. N Engl J Med 310: 347–352
Ehsani AA, Ogawa T, Miller TR, Spina RJ, Jilka SM (1991) Exercise training improves left ventricular systolic function in older men. Circulation 83: 96–103
Eichhorn EJ, Bedotto JM, Balloy CR et al. (199ob) Effect of ß-adrenergic blockade on myocardial function and energetics in congestive heart failure. Circulation 82: 473–483
Eichhorn EJ, Heesch CM, Barnett JH et al. (1994) Effect of metoprolol on function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, doubleblind, placebo-controlled study. J Am Coll Cardiol 24: 1310–1320
Eichhorn EJ, Jeesch CM, Risser RC, Marcoux L, Hatfield B (199oa) Predictors of systolic and diastolic improvement in patients with dilated cardiomyopathy treated with metoprolol. J Am Coll Cardiol 25: 154–162
Elkayam U, Amin J, Mehra A et al. (1990) A prospective, randomized double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide di-nitrate and their combination in the treatment of chronic heart failure. Circulation 82: 1954–1961
Ellbogen DA, Mohanty PK, Szentpetery S, Thames MD (1989) Arterial baroreflex abnormalities in heart failure: Reversal after orthotopic cardiac transplantation. Circulation 79: 51–58
Engelmeier RS, GConnell JB, Walsh R, Rad N, Scanlon PJ, Gunnar RM (1985) Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: double-blind, randomized, placebo-controlled trial. Circulation 72: 536–546
Erdmann E (1984) Therapie der akuten and chronischen Herzinsuffizienz mit Herzglykosiden. In: Riecker G (Hrsg) Handbuch der inneren Medizin. Springer, Berlin Heidelberg New York Tokio,S 563–656
Erdmann E, Brown L, Kreuzer E, Kemkes B, Weinhold C, Holper K, Klövekorn W (1985a) Altersabhängige Regulation der Herzglykosidrezeptoren. Z Kardiol [Suppl 7] 74: 33–38
Erdmann E, Presek P, Swozil R (1976) Über den Einfluß von Kalium auf die Bindung von Strophanthin an menschliche Herzmuskelzellmembranen. Klin Wochenschr 54: 383–389
Erdmann E, Werdan K, Brown L (1985b) Multiplicity of cardiac glycoside receptors in the heart. Trends Pharmacol Sci 6: 293–295
Eriksson H, Svärdsudd K, Larsson B et al. (1989) Risk factors for heart failure in the general population: The study of men born in 1913. Eur Heart J to: 647–656
Eschenhagen T, Mende U, Nose M et al. (1991) Isoprenaline-induced increase in m-RNA levels of inhibitory G-protein-a-subunits in rat heart. Naunyn Schmiedebergs Arch Pharmacol 343: 609–615
Eschenhagen T, Mende U, Nose M et al. (1992a) Increased messenger RNA level of the inhibitory G-protein-a-subunit-Gice2 in human endstage heart failure. Circ Res 7o: 688–696
Eschenhagen T, Mende U, Schmitz W, Scholz H (1992b) Veränderungen der Genexpression bei terminaler Myokardinsuffizienz. Z Kardiol 81 (Supp14): 33–40
Esler MD, Thompson JM, Kaye DM et al. (1995) Effects of aging on the responsiveness of the human cardiac sympathetic nerves to stressors. Circulation 91: 351–358
Fabiato A (1975) Dependence of the contractile activation of skinned cardiac cells the sarcomere length. Nature 256: 54–56
Fabiato A (1983) Calcium-induced release of calcium from the cardiac s.r. Am J Physiol 245: CI-C14
Farrar DJ, Hill JD, Gray jr LA et al. (1988) Heterotopic prostetic ventricles as a bridge to cardiac transplantation. N Engl J Med 318: 333–340
Fazio S, Cittadini A, Cuocolo A et al. (1993) J Clin Endocrinol Metab 77: 790–793
Fazio S, Sabatini D, Capaldo D et al. (1996) A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 334: 809–814
Feldman AM, Bristow MR, Parmley WW et al., for the Vesnarinone Study Group (1993) Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 329: 149–155
Feldman AM, Cates AE, Bristow MR, Dop C van (1989) Altered expression of a-subunits of G-proteins in failing human hearts. J Mol Cell Cardiol 21: 359–365
Feldman AM, Cates AE, Veazey WB et al. (1988b) Increase of the 40000-mo1 wt pertussis toxin substrate ( G protein) in the failing human heart. J Clin Invest 82: 189–197
Feldman AM, Jackson DG, Bristow MR, Cates AE, Dop C van (1991a) Immunodetectable levels of the inhibitory guanine nucleotide binding regulatory proteins in failing human heart: disordance with measurements of adenylate cyclase activity and levels of pertussis toxin substrate. J Mol Cell Cardiol 23: 439–452
Feldman AM, Ray PE, Silan CM et al. (1991b) Selective gene expression in failing human heart. Quantification of steady-state levels of messenger RNA in endomyocardial biopsies using the polymerase chain reaction. Circulation 83: 1866–1872
Feldman MD, Alderman JD, Arosty JM et al. (1988a) Depression of systolic and diastolic myocardial reserve during atrial pacing tachacardia in patients with dilated cardiomyopathy. J Clin Invest 82: 1661–1669
Feldman MD, Copelas L, Gwathmey JK et al. (1987) Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with endstage heart failure. Circulation 75: 331–339
Feldman MD, Gwathmey JK, Phillips P, Schoen F, Morgan JP (1988c) Reversal of the force-frequency-relationship in working myocardium from patients with endstage heart failure. J Appl Cardiol 3: 273–283
Feldman RD, Limbird LE, Nadeau J, Robertson D, Wood AJ (1984) Alterations in leukocyte [3-receptor affinity with aging: A potential explantation for altered 13-adrenergic sensitivity in the elderly. N Engl J Med 31o: 815–819
Ferguson DW (1990) Baroflex-mediated circulatory control in human heart failure. Heart Failure 6: 3–11
Ferguson DW, Abboud FM, Mark AL (1984) Selective impairment of baro-reflex-mediated vasoconstrictor responses in patient with ventricular dysfunction. Circulation 69. 451–460
Ferguson DW, Berg J, Sanders JS, Roach PJ, Kempf JS, Kienzle MG (1989) Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Circulation 8o: 65–77
Ferguson DW, Berg WJ, Sanders JS (1990) Clinical and hemodynamic correlates of sympathetic nerve activity in normal humans and patients with heart failure: evidence from direct neurographic recordings. J Am Coll Cardiol 16: 1125–1134
Flesch M, Kilter H, Cremers B et al. (1999) Effects of endotoxin on human myocardial contractility involvement of nitric oxide and peroxynitrite. J Am Coll Cardiol 33: 1062–1070
Flesch M, Kilter H, Cremers B et al. (1997) Acute effects of nitric oxide and cyclic GMP on human myocardial contractility. J Pharmacol Exp Ther 281: 1340–1349
Flesch M, Schwinger RHG, Schnabel P et al. (1996) Sarcoplasmatic reticulum Caz+ATPase and phospholamban mRNA and protein levels in end-stae heart failure due to ischemic or dilated cardiomyopathy. J Mol Med 74: 321–332
Fowler MB, Laser JA, Hopkins GL, Minobe W, Bristow MR (1986) Assessment of the ß-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation 74: 1290–1302
Francis GS, Benedict C, Johnstone DE et al., for the SOLVD Investigators (1990) Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. Circulation 82: 1724–1729
Francis GS, Goldsmith SR, Ziesch S, Nakajima H, Cohn JN (1985) Relative attenuation of sympathetic drive during exercise in patients with congestive heart failure. J Am Coll Cardiol 5: 832–839
Francis GS, Goldsmith SR, Ziesche SM, Cohn JN (1982) Response of plasma norepinephrine and epinephrine to dynamic exercise in patients with congestive heart failure. Am J Cardiol 49: 1152–1159
Frank O (1895) Zur Dynamik des Herzmuskels. Z Biol 32: 370–382
Frustraci A, Perrone GA, Gentiloni N, Russo MA (1992) Reversible dilated cardiomyopathy due to growth hormone deficiency.Am J Clin Pathol 97: 503–511
Fuster V, Stein B, Halperin JL, Chesebro JH (199o) Antithrombotic therapy in cardiac disease: an approach based on pathogenesis and risk stratification. Am J Cardiol 65: 38C-44 C
Gaffney TW, Braunwald E (1963) Importance of adrenergic nervous system in the support of circulatory function in patients with congestive heart failure. Am J Med 34: 320–324
Gage J, Rutman H, Lucido D, Le Jemtel TH (1986) Additive effects of dobutamine and amrinone on myocardial contractility and ventricular performance in patients with severe heart failure. Circulation 74: 367–373
Ganten D, Lindpaintner K, Ganten U et al. (1991) Transgenic rats: New animal models in hypertension research. Hypertension 17: 843–855
Gauthier C. Tavernier G, Charpentier F, Langin D, Le Marec H (1996) Functional 133-adrenoceptor in the human heart. J Clin Invest 98: 556–562
Genth-Zotz S, Zotz R, Geil S, Voigtländer T, Meyer J, Darius H (1999) Recombinant growth hormone therapy in patients with ischemic cardiomyopathy. Effects on hemodynamics, left ventricular function, and cardiopulmonary exercise capacity. Circulation 99: 18–21
Gheorghiade M, Hall V, Lakier JB, Goldstein S (1989) Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combinations in patients with severe heart failure. J Am Coll Cardiol 13: 134–142
Gilbert EM, Abraham WT, Olsen S et al. (1996) Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol vs. carvedilol in the failing heart. Circulation 94: 2817–2825
Gilbert EM, Anderson JL, Deitchman D et al. (199o) Long-term ß-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: A double blind, randomized study of bucindolol vs. placebo. Am J Med 88: 223–229
Gille E, Lemoine H, Ehle B, Kauman AJ (1985) The affinity of (-)propraolol for ß,- and 132-receptors of human heart. Differential antagonism of the positive inotropic effects and adenylate cyclase stimulation by (-)-noradrenaline and (-)-adrenaline. Naunyn Schmiedebergs Arch Pharmacol 331: 6o - 70
Gillebert TC, Sys SU, Brusaert DL (1989) Influence of loading patterns on peak length-tension relation and on relaxation in cardiac muscle. J Am Coll Cardiol 13: 483–490
Gilman AG (1984) G proteins and dual control of adenylate cyclase. Cell 36: 577–579
GISSI-3 (1994) Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after myocardial infarction. Lancet 343: 1115–1122
Gold MR, Feliciano Z, Gottlieb SS, Fisher ML (1995) Dual-chamber pacing with a short atrioventricular delay in congestive heart failure: A randomized study. J Am Coll Cardiol 26: 967–973
Goldberg LI (1989) Pharmacological bases for the use of dopamine and related drugs in the treatment of congestive heart failure. J Cardiovasc Pharmacol 14 (Suppl 8): 21–26
Goldsmith SR, Francis GS, Cowley AW (1986) Arginine vasopressin and the renal response to water loading in congestive heart failure. Am J Cardiol 58: 295–301
Goldstein RE, Boccuzzi SJ, Crues D (1991) Dilitazem increases late-onset congestive heart failure in postinfarction patients with early reductio in ejection fraction. Circulation 83: 52–60
Goodyer AVN, Jaeger CA (1955) Renal response to non-smoking hemorrhage: role of the autonomic nervous system and of the renal circulation. Am J Physiol 180: 69–74
Gorcsan III J, Feldman AM, Kormos RL et al. (1998) Heterogeneous immediate effects of partial left ventriculectomy on cardiac performance. Circulation 97: 839–842
Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL (1994) Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest 94: 1621–1628
Gottlieb SS, Dickstein K, Fleck E et al. (1993) Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 88: 1602–1609
Greef K (1977) Zur Pharmakokinetik des g-Strophanthins. Dtsch Med Wochenschr 102: 135–139
Green SA, Cole G, Jacinto M, Innis M, Liggett SB (1993) A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem 268: 23116–23121
Griendling KK, Murphy TJ, Alexander RW (1993) Molecular biolo- gy of the renin-angiotensin system. Circulation 87: 1816–1828
Grossman W (199o) Evaluation of systolic and diastolic function of the myocardium. In: Grossman W, Bairn D (eds) Cardiac Catheterization and Angiography, 4th edn, Lea and Febiger, Philadelphia, pp 319–342
Gulati J (1992) Length-sensing function of troponin C and Starlings Law of the heart. Circulation 85: 1954–1955
Gurevitch J, Frolkis I, Yuhas Y et al. (1996) Tumor necrosis factor-alpha is released from the isolated heart undergoing ischemia and reperfusion. J Am Coll Cardiol 28: 247–252
GUSTO Angiographie Investigators (1993) The effects of tissue plasminogen activation, streptokinase or both on coronary artery, patency, ventricular function and survival of the acut myocardial infarction. N Engl J Med 329: 1615–1622
Gwathmey JK, Copelas L, MacKinnon R et al. (1987) Abnormal intracellular calcium handling in myocardium form patients with end-stage heart failure. Cire Res 61: 7o - 76
Gwathmey JK, Morgan JP (1985) Altered calcium handling in experimental pressure-overload hypertrophy in the ferret. Cire Res 57: 836–843
Gwathmey JK, Slawsky MT, Hajjar RJ, Briggs GM, Morgan JP (1990) Role of intracellular calcium handling in force-interval relationships of human ventricular myocardium. J Clin Invest 85: 1599–1613
Habib FM, Springall DR, Davies GJ et al. (1996) Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet 347: 1151–1155
Hall AS, Murray GD, Ball SG (1997) Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE extension ( AIREX) study. Lancet 349: 1493–1497
Hasenfuss G (1992) Neue Kardiotonika/Inodilatatoren: Energetisehe Aspekte. Z Kardiol 81 (Suppl 4): 57–63
Hasenfuss G, Reinecke H, Studer R et al. (1994) Relation between myocardial function and expression of sarcoplasmic reticulum Caz+-ATPase in failing and nonfailing human myocardium. Cire Res 75: 4334–4343
Hasking GJ, Esler MD, Jennings EL (1986) Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nerve activity. Circulation 73: 615–621
Hausdorfer WP, Caron MG, Lelkowitz RJ (1990) Turning off the signal. Desensitization of 13-adrenergic receptor function. FASEB J 4: 2881–2889
Hegglin R (1934) Über Organvolumen and Organgewicht: Nebst Bemerkungen über die Größenbestimmungsmethoden. Z Konstitutionslehre 18: 110–134
Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB (1989) Increased I3-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation 79: 483–490
Helin K, Stoll M, Meffert S, Stroth S, Unger T (1997) The role of angiotensin receptors in cardiovascular diseases. Annals of Medicine 29: 23–29
Henderson AH (1994) Amiodarone for chronic failure. Lancet 344: 489–490
Hershberger RE, Feldman AM, Bristow MR (1991) Ai-Adenosine receptor inhibition of adenylate cyclase in failing and nonfailing human ventricular myocardium. Circulation 83: 1343–1351
Heublein DM, Wie C, Lerman A et al. (1994) Endothelin in human congestive heart failure. Circulation 89: 1580–1586
Hickam JB, Cargill WH (1948) Effects of exercise pressure in normal person and in patients with cardiovascular disease and pulmonary emphysema. J Clin Invest 27: 10–15
Higginbotham MB, Morris KG, Williams RS et al. (1986) Regulation of stroke volume during submaximal and maximal upright exercise in normal man. Circ Res 58: 281–291
Ho KK1, Anderson KM, Kannel WB, Grossman W, Levy D (1993) Survival after the onset of congestive heart failure in Framingham heart study subjects. Circulation 88: so7–115
Hochleitner M, Hörtnagl H, Ng C-K et al. (1990) Usefulness of physiologic dual-chamber pacing in drug-resistant idiopathic dilated cardiomyopathy. Am J Cardiol 66: 198–202
Honerjäger P, Heiss A, Schäfer-Korting M, Schönsteiner G, Reiter M (1984) UDCG-n5–a cardiotonic pyridazinone which elevates cyclic AMP and prolongs the action potential in guinea-pig papillary muscles. Naunyn Schmiedebergs Arch Pharmacol 325: 259–269
Hoppe UC et al, Deutsche Gesellschaft für Kardiologie Herz-and Kreislaufforschung (1998) Leitlinien zur Therapie der chronischen Herzinsuffizienz. Z Kardiol 87: 645–661
Hort W (1955) Qunatitative Untersuchungen über die Kapillarisierung des Herzmuskels im Erwachsenen-and Greisenalter, bei Hypertrophie and Hyperplasie.Virchows Arch [Pathol Anat] 327: 56o - 576
Hort W (1968) Morphologie der akuten and chronischen Herzdilatation and Herzinsuffizienz. Verh Dtsch Ges Kreislaufforsch 34: 1–15
Hulsmann WC (1991) Biochemical profile of propionyl-L-carnitine. Cardiovasc Drugs Ther 5 (Suppl I): 7–10
Hunkeler NM, Kullman J, Murphy AM (1991) Troponin I isoform expression in human heart. Circ Res 69: 1409–1414
Huxley H (1969) The mechanism of muscular contraction. Science 164: 1356–1361
Investigators of the Study on Propionyl-L-Carnitine in Chronic Heart Failure (1999) Study on propionyl-L-carnitine in chronic heart failure. Eur Heart J 19: 7o - 76
Ishikawa T,Yanagisawa M, Kimura S, Goto K, Masaki T (1988) Positive inotropic action of novel vasoconstrictor peptide endothelin on guinea pig atria. Am J Physiol 225: H97o-H973
ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group* (1995) ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 345: 669–685
Isoyama S, Grossman W, Wei JY (1988) Effect of age on myocardial adaptation to volume overload in the rat. J Clin Invest 81: 185o - 1857
Isoyama S, Wei JY, Izumo S, Fort P, Schoen FJ, Grossman W (1987) Effect of age on the development of cardiac hypertrophy produced by aortic constriction in the rat. Circ Res 61: 337–345
Ito H, Hiroe M, Hirata Y et al. (1993) Insulinlike growth factor-I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes. Circulation 87: 1715–1721
Izumo S, Nadal-Ginard B, Mandavi V (1988) Protooncogene induclion and reprogramming of cardiac gene expression produced by pressure overload. Proc Natl Acad Sci USA 85: 339–343
Kaddoura S, Firth JD, Boheler KR, Sudgen PZH, Poole-Wilson PA (1996) Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo. Circulation 93: 2068–2079
Kajstura J, Cigola E, Malhotra A et al. (1997) Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol 29: 859–87o
Kajstura J, Leri A, Finato N et al. (1998) Myocyte proliferation in end-stage cardiac failure in humans. Proc Natl Acad Sci USA 95 (15) 8801–8805
Kannel WB, Cupples A (1988) Epidemiology and risk of cardiac failure. Cardiovasc Drugs Ther 2: 387–395
Kannel WB, Plehn JF, Cupples A (1988) Cardiac failure an sudden death in the Framingham Study. Am Heart J 115: 869–875
Kass DA (1991) Evaluation of left ventricular systolic function. Heart Failure 4: 198–205
Kass DA, Baughman KL, Pak PH, Cho PW, Levin HR, Gardner TJ, Halperin HR, Tsitlik JE, Acker MA (1995) Reverse remodeling from cardiomyopasty in human heart failure. External constraint vs. active assist. Circulation 91: 2314–2318
Kass DA, Manghan WL (1988) From Emax to pressure volume relations: A broader view. Circulation 77: 1203–1211
Katz AM (1990) Cardiomyopathy of overload. N Engl J Med 322: 100-no
Kaumann A), Lemoine H (1987) 32-Adrenoceptor-mediated positive inotropic effect of adrenaline in human ventricular myocardium. Quantitative discrepancies with binding and adenylate cyclase stimulation. Naunyn Schmiedebergs Arch Pharmacol 335: 403–411
Kelly RA, Eid H, Kramer Bk et al. (1990) Endothelin enhances the contractile responsiveness of adult rat ventricular myocytes to calcium via a pertusis toxin-sensitive pathway. J Clin Invest 86: 1164–1171
Kentish JC (1988) The length-tension relation in the failing myocardium and ist cellular basis. Heart Failure 4: 125–136
Kithas PA,Artman M, Thompson WJ, Strada SJ (1988) Subcellular distribution of high affinity type IV cyclic AMP phosphodiesterase activity in rabbit ventricular myocardium: relations to the effects of cardiotonic drugs. Circ Res 62: 782–786
Kokkonen JO, Saarinen J, Kovanen PT (1997) Regulation of local angiotensin II formation in the human heart in the presence of interstitial fluid. Circulation 95: 1455–1463
Komoro I, Kurabayashi M, Takaku F, Yazaki Y (1988) Expression of cellular oncogene in the myocardium during the development stage and pressure-overload hypertrophy of the rat hearts. Circ Res 62: 1075–1083
Komuro I, Kurabayashi M, Shibazaki Y, Takaku F, Yazaki Y (1989) Molecular cloning and characterization of CA2++Mg2+_dependent adenosine triphosphatase from rat cardiac sacroplasmic reticulum. Regulation of its expression by pressure overload and developmental stage. J Clin Invest 83: 1102–1108
Konstam MA, Rousseau MF, Kronenberg MW et al. (1992) Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. Circulation 86: 431–438
Krown KA, Page MT, Nguyen C et al. (1996) Tumor recrosis factor a-induced apoptosis in cardia myocytes: involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 98: 2854–2865
Krown KA, Yasui K, Brooker MJ et al. (1995) TNFa receptor expression in rat cardiac myocytes..: TNFa inhibition of L-type Cat+ current and Ca2+transients. FEBS Lett 376: 24–30
Kubo SH, Gollub S, Bourge R et al. (1992) Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure–results of a multicenter trial. Circulation 85: 942–949
Kubo SH, Rector TS, Heifetz SM, Cohn JN (1989) a2-receptor-mediated vasoconstriction in patients with congestive heart failure. Circulation 8o: 166o - 1669
Kurabayashi M, Shibasaki Y, Komuro I, Tsuchimochi H, Yazaki Y (1990) The myosyn switching in human cardiac hypertrophy. Jpn Circ J 54: 1192–1205
Kyriakides ZS, Kelesides K, Melanidis J et al. (1986) Systolic functional response of normal older and younger adult left ventricles to dobutamine. Am J Cardiol 58: 816–819
Lakatta EG (1993) Deficient Neuroendocrine Regulation of the Cardiovascular System With Advancing in Healthy Humans. Circulation 87: 631–636
Lakatta EG, Jewell BR (1977) Length-dependent activation. Its affect on the length-tension relation in cat ventricular muscle. Circ Res 40: 251–257
Laks MM, Morady F, Swan MB (1973) Myocardial hypertrophy produced by chronic infusion of subhypertensive doses of norepinephrine in the dog. Chest 64: 75–78
Lambertz H, Meyer J, Erbel R (1984) Long-term hemodynamic effects of prenalterol in patients with severe congestive heart failure. Circulation 69: 298–306
Lands AM, Arnold A, McAuliff JP, Luduena FP, Brown TG (1967) Differentiation of receptor systems activated by sympathomimetic amines. Nature 214: 597–598
Le Jemtel TH, Keung E, Sonnenblick EH et al. (1979) Amrinone: a new non-glycosidic, non-adrenergic cardiotonic agent effective in the treatment on intractable myocardial failure in man. Circulation 59: 1098–1106
Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP (1998) Clinical effects of f3-adrenergic blockade in chronic heart failure. Circulation 98: 1184–1191
Lee CO, Kang DH, Sokol JG, Lee KS (1980) Relation between intracellular Na+-ion activity and tension of sheep cardiac purkinje fibers exposed to dihydroouabain. Biophys J 29: 315–330
Lee DC-S, Johnson RA, Goroll AH, Newell JB, Strauss WH, Haber E (1982) Heart failure in outpatients. A randomised trial of digoxin vs. placebo. N Engl J Med 306: 699–705
Levine TB, Francis GS, Goldsmith SR, Cohn JN (1983) The neuro-humoral and hemodynamic response to orthostatic tilt in patients with congestive heart failure. Circulation 67: 1070–1075
Levine TB, Francis GS, Goldsmith SR, Simon A, Cohn JN (1982) Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relationship to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 49: 1659–1666
Levine TB, Kalman J, Mayer L, Fillit HM’ Packer M (1990) Elevated circulating levels of tumor necrosis factor in congestive heart failure. N Engl J Med 323: 236–241
Levitsky D, De la Bastie D, Schwartz K, Lompré AM (1991) Caz+ATPase and function of sarcoplasmic reticulum during cardiac hypertrophy. Am J Physiol (Suppl) 261: 23–26
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456–62
Liggett SB, Wagoner LE, Craft LL, Hornung RW, Holt BD, McIntosh TC (1998) The he 164 32 adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest 102: 1534–2539
Limas CJ, Olivari M-T, Goldenberg IF, Levine RB, Benditt DG, Simon A (1987) Calcium uptake by cardiac sarcoplasmic reticulum in human dilated cardiomyopathy. Cardiovasc Res 21: 601–605
Linzbach AJ (1956) Über das Längenwachstum der Herzmuskel-fasern and ihrer Kerne in Beziehung zur Herzdilatation. Virchows Arch [Pathol Anat] 328: 165
Linzbach AJ,Akuomoa-Boateng E (1973) Die Altersveränderungen des menschlichen Herzens: I Das Herzgewicht im Alter. Klin Wochenschr 51: 156–163
Löffelholz K, Pappano A (1985) The parasympathetic neuroeffector junction of the heart. Pharmacol Rev 37: 1–24
Lompré AM, Lambert F, Lakatta EG, Schwartz K (1991a) Expression of sarcoplasmic reticulum Ca“-ATPase and calsequestrin genes in rat heart during ontogenic development and aging. Circ Res 69: 1380–1388
Lompré AM, Mercadier JJ, Schwartz K (1991b) Changes in gene ex- pression during cardiac growth. Int Rev Cytol 124: 137–186
Lorell BH (1988) Left ventricular diastolic pressure-volume relations: Understanding and managing congestive heart failure. Heart Failure 4: 206–223
Lowes BD,Minobe W,Abraham WT et al. (1997) Changes in gene expression in the intact human heart. Downregulation of ot-myosin heavy chain in hypertrophied, failing ventricular myocardium. Clin Invest loo: 2315–2324
Maciel LMZ, Polikar R, Rohrer D, Popovich BK, Dillmann WH (1990) Ageinduced decreases in the messenger RNA coding for the sarcoplasmic reticulum Ca’-ATPase of the rat heart. Circ Res 69: 230–234
Makino N, Hata T, Sugano M, Dixon IMC, Yanaga T (1996) Regression of hypertrophy after myocardial infarction is produced by the chronic blockade of angiotensin type 1 receptor in rats. J Mol Cell Cardiol 28;: 507–517
Mann DL, Kent RI, Parsons B, Cooper G (1992) Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 85: 790–804
Massie B, Bourassa M, DiBianco R et al. (1985) Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial. Circulation 71: 963–971
Matsumori A, Ono K, Nishio R, Nose Y, Sasayama S (1997) Amiodarone inhibits production of tumor necrosis factor-aby human mononuclear cells. A possible mechanism for its effect in heart failure. Circulation 96: 1386–1389
Mc Murray JJV, Ray SG, Abdulla I, Dargie HD, Morton JJ (1992) Plasma endothelin in chronic heart failure. Circulation 85: 1374–1379
McKnee PA, Castelli WP, McNamara PM, Kannel WB (1971) The natural history of congestive failure: the Framingham Study. N Engl J Med 285: 1441–1446
McMurray JJV (1998) Failure to practice evidence-based medicine: why do physicians not treat patients with heart failure with angiotensin-converting enzyme inhibitors? Eur Heart J 19: (Suppl I) Ls5-Lzs
Mercadier JJ, Bouveret P, Gorza L et al. (1983) Myosin isoenzymes in normal and hypertrophied human ventricular myocardium. Circ Res 53: 52–62
Mercadier JJ, Lompre AM, Duc P et al. (1990) Altered sacroplasmic reticulum Ca’-ATPase gene expression in the human ventricle during end-stage heart failure. J Clin Invest 85: 305–309
Merit-HF Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 353: 2001–2007
Merola B, Cittadini A, Colao A et al. (1993) Cardiac structural and functional abnormalities in adult patients with growth hormone deficiency. J Clin Endocrinol Matab 77: 1658–1661
Miller CA, Pae WE, Pierce WS (1990) Combined registry for the clinical use of mechanical ventricular assist pumps and the total artificial heart in conjunction with heart transplantation: 4th official report–1989. J Heart Transplant 9: 453–458
Miller LW (1991) Mechanical assist devices in intensive cardiac care. Am Heart J 121: 1887–1892
Misao J, Hayakawa Y, Ohno M, Kato S, Fujiwara T, Fujiwara H (1996) Expression of bel-z Protein, an inhibitor of apoptosis, and box, an accelerator of apoptosis, in ventricular myocytes of human hearts with myocardial infarction. Circulation 94: 1506–1512
Molenaar P, OReilly G, Sharkey A et al. (1993) Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circ Res 72: 526–538
Morgan HE, Baker KM (1991) Cardiac hypertrophy: mechanical, neural and endocrine dependence. Circulation 83: 13–25
Morgan J (1991) Abnormal intracellular modulation of calcium as a major cause of cardiac contractile dysfunction. N Engl J Med 325: 626–632
Morley JE, Reese S (1989) Clinical implications of the aging heart. Am J Med 86: 77–86
Movsesian MA, Bristow MR, Krall J (1989) Caz+-uptake by cardiac sarcoplasmic reticulum from patients with idiopathic dilated cardiomyopathy. Circ Res 65: 1141–1144
Movsesian MA, Colyer J, Wang JH, Krall J (1990) Phospholambanmediated stimulation of Caz+-uptake in sarcoplasmic reticulum from normal and failing hearts. J Clin Invest 85: 1698–1702
Movsesian MA, Smith CJ, Krall J, Bristow MR, Manganiello VC (1991) Sarcoplasmatic reticulum-associated cyclic adenosine 5`-monophosphate phosphodiesterase activity in normal and failing human hearts. J Clin Invest 88: 15–19
MRC Working Party (1992) Medical Research Council trial of treatment of hypertension in older adults: principal results. BMI 304: 405–412
Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ (1993) Expression cloning of type 2 angiotensin II receptor of a unique class of seven membrane receptors. J Biol Chem 268: 24539–24542
Mulieri LA, Hasenfuss G, Leavitt B, Allen PD, Alpert NR (1992) Altered myocardial force-frequency relation in human heart failure. Circulation 85: 1743–1750
Müller FU, Boheler KR, Eschenhagen T, Schmitz W, Scholz H (1993) Isoprenaline stimulates gene transcription of the inhibitory G protein a-subunit Gia2 in rat heart. Circ Res 72: 696–700
Münzel T, Giaid A, Kurz S, Stewart DJ, Harrison DG (1995a) Evidence for a role of endothelin 1 and protein kinase C in nitroglyarine tolerance. Proc Natl Acad Sci 92: 5244–5248
Münzel T, Sayegh H, Freeman BA, Tarpey MM, Harrison DG (1995b) Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross tolerance. J Clin Invest 95: 187–194
Murphy TH Takeuchi K, Alexander RW (1992) Molecular cloning of AT 1 angiotensin receptors. Am J Hyperten 5: 236–242
Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE (1991) Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 351: 233–236
Näbauer M, Beuckelmann DJ, Erdmann E (1993) Characteristics of transient outward current in human ventricular myocytes from patients with terminal heart failure. Circ Res 73: 386–394
Nagai R, Zarain-Herzberg A, Brandl CJ et al. (1989) Regulation of myocardial Cat+-ATPase and phospholamban m-RNA expression in response to pressure overload and thyroid hormone. Proc Natl Acad Sci USA 86: 2966–2970
Nagasaki K, Fleischer S (1988) Ryanodine sensitivity of the calcium release channel of sarkoplasmic reticulum. Cell Calcium 9: 1–7
Nakao K, Minobe W, Roden R, Bristow MR, Leinwand LA (1997) Myosin heavy chain gene expression in human heart failure. J Clin Invest 100: 2362–2370
Narayanan N (1981) Differential alterations in ATP-supported calcium transport activities of sarcoplasmic reticulum and sarcolemma of aging myocardium. Biochim Biophys Acta 678: 442–459
Narula J, Haider N, Virmani R et al. (1996) Apoptosis in myocytes in end-stage heart failure. N Engl J Med 335: 1182–1189
NETWORK Investigators (1998) Clinical outcome with enalapril in symptomatic chronic heart faillure; a dose comparison. Eur Heart J19: 481–489
Neumann J, Schmitz W, Scholz H et al. (1988) Increase in myocardial Gi-proteins in heart failure. Lancet 2: 936–937
Nguyen QT, Cernacek P, Calderoni A et al. (1998) Endothelin a receptor blockade causes adverse left ventricular remodeling but improves pulmonary artery pressure after infarction in the rat. Circulation 98: 2323–2330
Nickenig G, Böhm M (1998) Cardiac specific expression of ATs receptors in experimental heart failure. Heart Failure Reviews 3: 101–107
Nickenig G, Böhm M (1998) Vaskuläre AL-Rezeptoren bei arterieller Hypertonie and metabolischem Syndrom. Herz Kreisl 30: 329–334
Nilius B, Hess P, Lansman JB, Tsien RW (1985) A novel type of car- diac calcium channel in ventricular cells. Nature 316: 443
Nul DR, Doval HC, Grancelli HO et al., for the GESICA-GEMA Investigators (1997) Heart rate is a marker of amiodarone mortality reduction in severe heart failure. J Am Coll Cardiol 29: 1199–1205
Ogawa T, Spina RJ, Martin III WH et al. (1992) Effects of aging, sex, and physical training on cardiovascular responses to exercixe. Circulation 86: 494–503
Ohlshausen KE et al., for the German and Austrian Xamoterol Study Group (1988) Double-blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure. Lancet I: 489–493
Ohlsson A, Beck R, Bennett T et al. (1995) Monitoring of mixed venous oxygen saturation and pressure from biosensors in the right ventricle. A 24 hour study in patients with heart failure. Eur Heart J 16: 1215–1222
Ohnhaus EE (1983) Dosierung von Herzglykosiden. In: Erdmann E (Hrsg) Therapie mit Herzglykosiden. Springer, Berlin Heidelberg New York Tokio, S 40–47
Olivari MT, Levine TB, Cohn JN (1983) Abnormal neurohumoral response to nitroprusside infusion in congestive heart failure. J Am Coll Cardiol 2: 411–417
Olivetti G, Abbi R, Quaini F et al. (1997) Apoptosis in the failing human heart. N Engl J Med 336 /16: 1131–1141
Olivetti G, Melissari M, Capasso JM, Anversa P (1991) Cardiomyopathy of the aging human heart. Myocyte loss and reactice cellular hypertrophy. Circ Res 68: 1560–1568
Olsen SL, Gilbert EM, Renlund DG et al. (1995) Carvedilol improves left ventricular function and symptoms in chronic heart failure: A double-blind randomized study. J Am Coll Cardiol 25: 1225–1231
Oral H, Dorn GW, Mann DL (1997) Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-a in the adult mammalian cardiac myocyte. J Biol Chem 272: 3836–4842
Orchard CH, Lakatta EG (1985) Intracellular calcium transients and developed tension in rat heart muscle. A mechanism for the negative-interval-strength relationship. J Gen Physiol 86: 637–651
Osterziel KJ, Strohm O, Schuler J et al. (1998) Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 351: 1233–1237
Otsu K, Willard HF, Khanna VK et al. (1990) Cloning of cDNA encoding the Cat+-release channel (ryanodine receptor) of rabbit cardiac muscle sarcoplasmic reticulum. J Biol Chem 265: 13472–13483
Packer M (1987a) Do vasodilators prolong life in heart failure? N Engl J Med 316: 1471–1473
Packer M (1987b) How should we judge the efficacy of drug therapy in patients with chronic congestive heart failure? The insights of six blind men. J Am Coll Cardiol 9: 433–438
Packer M (1989a) Is activation of the sympathetic nervous system beneficial or detrimental to the patient with chronic heart failure? Lessons learned from clinical trials with ß-adrenergic agonists and antagonists. J Cardiovasc Pharmaco114 (Suppl 5 ): 38
Packer M (1989b) Pathophysiological mechanismus underlying the adverse effects of calcium channel-blocking drugs in patients with chronic heart failure. Circulation 8o (Suppl IV): IV59-IV-67
Packer M (1992) Pathophysiology of chronic heart failure. Lancet 340: 88
Packer M for the RADIANCE-Study (1993) Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med 329: 1–7
Packer M, Bristow MR, Cohn JN et al. (1996) The effect of carvediloi on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334: 1348–1355
Packer M, Carver JR, Rodeheffer RJ et al. (1991) Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 325: 1468
Packer M, Caspi A, Charlton V et al. (1998) Arteriosclerosis, thrombosis and vascular biology, basic science/circulation, cardiopulmonary and critical care, high blood pressure research, kidney: Hormonal, metabolic and immunologic modulation in heart failure. Circulation 98: (Supple) 3
Packer M, Cohn JN (1999) Concensus recommendations forthe management of chronic heart failure. Am J Cardiol 83 (Suppl): 1A-38 A
Packer M, Lee WH, Kessler PD, Gottlieb SS, Medina N, Yushak M (1987) Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med 317: 799–804
Packer M, Medina N, Yushak M (1984) Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure. Circulation 7o: 1038–1046
Pardee H (1942) Nomenclature and criteria for diagnosis of diseases of the heart. NYHA, New York, pp 9–10
Parsons WJ, Ramkumar V, Stiles GS (1988) The new cardiotonic drug sulmazole is an Ai-adenosine receptor antagonist and functionally blocks the inhibitory regulator Gi. Mol Pharmacol 33: 441–449
Paul M, Bachmann J, Ganten D (1992) The tissue renin-angiotensin systems in cardiovascular disease. Trends Cardiovasc Med 2: 94–99
Petrou M, Clarke S, Morrison K, Bowles C, Dunn M, Yacoub M (1999) Clenbuterol increases stroke power and contractile speed of skeletal muscle for cardia assist. Circulation 99: 713–729
Pfeffer MA, Braunwald E, Moyé LA et al. (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 327: 669–677
Pfisterer ME, Kiowski W, Burckhardt D, Follat F, Burkart F (1992) Beneficial effect of amiodarone on cardiac mortality in patients with asymptomatic complex ventricular arrhythmias after acute myocardial infarction and preserved but not impaired left ventricular function. Am J Cardiol 69: 1399–1402
Philbin EF (1998) Factors determining angiotensin-converting enzyme inhibitor underutilization in heart failure in a community setting. Clin Cardiol 21: 103–108
Pieske B, Beyermann B, Breu V, Löffler BM, Schlotthauer K, Maier LS, Schmidt-Schweda S, Just H, Hasenfuss G (1999) Functional effects of endothelin and regulation of endothelin receptors in isolated human nonfailing and failing myocardium. Circulation 99: 1802–1809
Pitt B, Segal R, Martinez FA et al., on behalf of ELITE Study Investigators (5997) Randomised trial of losartan vs. captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349: 747–752
Plotnick GD, Becker LC, Fisher ML et al. (1986) Use of the Frank-Starling mechanism during submaximal vs. maximal upright exercise. Am J Physiol 251: HL1o1-H11o5
Pönicke K, Vogelsang M, Heinroth M et al. (1998) Endothelin-receptors in the failing and non-failing human heart. Circulation 97: 744–751
Poole-Wilson PA (1983) Hypokalemia induced by thiazide diuretics in the treatment of hypertension: a cause of concern, not nihilism. Postgrad Med 59 (Suppl 3): 137–139
Port JD, Gilbert EM, Larrabee P (199o) Neurotransmitter depletion compromises the ability of indirect acting amines to provide inotropic support in the failing human heart. Circulation 81: 929–938
Port S, Cobb FR, Coleman RE, Jones RH (198o) Effect of age on the response of the left ventricular ejection fraction to exercise. N Engl J Med 303: 1133–1137
Pousset F, Isnard R, Lechat P, Kalotka H, Carayon A, Maistre G, Escolano S, Thomas D, Komajda M (1998) Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J 18: 254–258
Pratt CM, Camm JA, Cooper W et al., for the SWORD Investgators (1998) Mortality in the survival with oral D-Sotalol ( SWORD) trial: Why did patients die? Am J Cardial 81: 869–876
Raifer SI, Rossen JD, Douglas FL, Goldberg LI, Karrison T (1986) Effects of long-term therapy with oral ibopamine on resting hemodynamics and exercise capacity in patients with heart failure: relationship to the generation of N-methyl-dopamine and to plasma norepinephrine levels. Circulation 73: 740–748
RALES Investigators (1996) Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure [the randomized aldactone evaluation study (RALES)]. Am J Cardiol 78: 902–907
Rasmussen PR, Minobe W, Bristow MR (199o) Calcium antagonist binding sites in failing and non failing ventricular myocardium. Biochem Pharmacol 39: 691–696
Raya T, Fonken SJ, Lee RW et al. (1991) Hemodynamic effects of direct angiotensin II blockade compared to converting enzyme inhibition in rat model of heart failure. Am J Hypertens 4: 334–340
Rector TS, Olivari MT, Levine TB, Francis GS, Cohn JN (1987) Predicting survival for an individual with congestive heart failure using the plasma norepinephrine concentration. Am Heart J 114: 148–152
Reichman ItT, Joyo Cl, Dembitsky WP et al. (199o) Improved patient survival after cardiac arrest using a cardiopulmonary support system. Ann Thorac Surg 49: 101–105
Reinecke H, Studer R, Eschenhagen T et al. (1993) Erhöhte Genexpression des kardialen Na+/Ca2+-Austauschers im insuffizienten menschlichen Myokard. Z Kardiol 8z (Suppl): 20
Reiter M (1988) Calcium mobilization and cardiac inotropic mechanisms. Pharmacol Rev 4o: 189–217
Remes J, Reunanen A, Aromaa A, Pyörälä K (1992) Incidence of heart failure in eastern Finland: a population-based surveillance study. Eur Heart J 13: 588–593
Reuter H (1983) Calcium channel modulation by neurotransmitters, enzymes and drugs. Nature 3o1: 569–574
Reynolds DW, Bartelt N, Taephe R, Bennett TD (1995) Measurement of pulmonary artery diastolic pressure from the right ventricle. J Am Coll Cardiol 25: 1176–1182
Rodbell M (198o) The role of hormone receptors and GTP-regulatory proteins in membrane transduction. Nature 284: 17–22
Rodeheffer RJ, Gerstenblith G, Becker LC, Fleg JL, Weisfeldt ML, Lakatta EG (1984) Exercise cardiac output is main-tained with advancing age in healthy human subjects: Cardiac dilation in increased stroke volume compensate for a diminished heart rate. Circulation 69: 203–213
Rolandi E, Sabino F, Cantoni V et al. (1989) Long-term therapy of chronic congestive heart failure with ibopamine: a multicenter trial. J Cardiovasc Pharmaco114 (Suppl 8 ): 93–101
Rosenthal JH, Pfeiffer B, Mecheilor ML et al. (1984) investigations of components of the renin-angiotensin system in rat vascular tissue. Hypertension 6: 383–392
Rowles JR, Mortimer BJ, Olsen DB (1993) Ventricular assist and total artificial heart devices for clinical use in 1993. ASAIO J 39: 840–855
Sadoshima J, Xu Y, Slayter HS, Izumo S (1993) Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 75: 977–984
Sakai M, Danzinger RS, Xiao RP, Spurgeon HA, Lakatta EG (1992) Contractile response of individual cardiac myocytes to norepinephrine declines with senescence. Am J Physiol 262: H184 - H189
Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y (1996) Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 383: 353–355
Sasaki K,Yamano Y, Bardhan S et al. (1991) Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II typ-1 receptor. Nature 351: 230–232
Sasse S, Brand NJ, Kyprianou P et al. (1993) Troponin-I-gene expression during human cardiac development and in end-stage heart failure. Circ Res 72: 932–938
Satoh M, Nakamura M, Tamura G, Makita S, Segawa I, Tashiro A, Satodate R, Hiramori K (1997) Inducible nitric oxide synthase and tumor necrosis factor-alpha in myocardium in human dilated cardiomyopathy. J Am Coll Cardiol 29: 716–724
Schieffer B, Wirger A, Meybrunn M et al. (1994) Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 89: 2273–2282
Schmitz W, Leyen H von der, Meyer W, Neumann J, Scholz H (1989) Phosphodiesterase inhibition and positive inotropic effects. J Cardiovasc Pharmacol 14 (Suppl 3): 11–14
Schnabel P, Böhm M, Gierschik P, Jakobs K-H, Erdmann E (1990) Improvement of cholera toxin-catalyzed ADP-ribosylation by endogenous ADP-ribosylation factor from bovine brain provides evidence for an unchanged amount of Gsa in failing human myocardium. J Mol Cell Cardiol 22: 73–82
Schnabel P, Mies F, Böhm M (1999) Hormontherapie bei Herzinsuffizienz: Wachstumshormon and Insulin-like-growth factor-I. Z Kardiol 88: 1–9
Scholz H (1986) Positive inotropic agents: different mechanism of action. In: Erdmann E, Greef K, Skou JC (eds) Cardiac Glycosides 1785–1985: Steinkopff Darmstadt, pp 181–188
Schunkert H, Dzau VJ, Tang SS et al. (199o) Increased rat cardiac angiotensin converting enzyme activity and m-RNA expression in pressure overload left ventricular hypertrophy: Effects on coronary restistance, contractility, and relaxation. J Clin Invest 86: 1913–1923
Schüren KP, Hüttemann U (1974) Chronisch obstructive Lungenerkrankungen: Die hämodynamische Wirkung von Digitalis beim chronischen Cor pulmonale in Ruhe and unter Belastung. Klin Wochenschr 52: 736–746
Schwartz K, Beckmann J, Dufour C et al. (1992) Exclusion of cardiac myosin heavy chain and actin gene involvement in hypertrophic cardiomyopathy of several french families. Circ Res 71: 3–8
Schwinger RHG, Böhm M, Erdmann E (1990) Evidence against spare or uncoupled ß-adrenoceptors in the human heart. Am Heart J 119: 899
Schwinger RHG, Böhm M, Erdmann E (1992) Inotropic and lusitropic dysfunction in myocardium from patients with dilated cardiomyopathy. Am Heart J 123: 116–128
Schwinger RHG, Böhm M, Mittmann C, La Rosée K, Erdmann E (1991) Evidence for a sustained effectiveness of sodium-channel activators in failing human myocardium. J Mol Cell Cardiol 23: 461–471
Schwinger RHG, Böhm M, Müller-Ehmsen J et al. (1993) Effect of inotropic stimulation on the negative force-frequency relationship in the failing human heart. Circulation 88: 2267–2276
Sharow VG, Sabbah HN, Shimoyama H et al. (1996) Evidence of cardiocyte apoptosis in myocardium of dogs with chronic heart failure. Am J Pathol 148: 141–1149
SHEP Cooperative Research Group (1991) Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in Elderly Program (SHEP). JAMA 265: 3255–3264
Sheu SS, Blaustein MP (1986) Sodium/calcium exchange and regulation of cell calcium and contractility in cardiac muscle, with a note about vascular smooth muscle. In: Fozzard HA (ed) The heart and cardiovascular system. Raven, New York, pp 509–535
Siliprandi N, Di Lisa F, Menabö R (1991) Propionyl-L-carnitine: biochemical significance and possible role in cardiac metablolism. Cardiovas Drugs Ther (Suppl I): 17–24
Simonton CA, Daly PA, Kereiakes D, Modin G, Chatterjee K (1987) Survival in severe left ventricular failure treated with the new nonglycosidic, nonsympathomimetic oral inotropic agents. Chest 92: 118–124
Simpson P (1983) Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an a,-adrenergic response. J Clin Invest 72: 732
Singh SN, Fletcher RD, Fisher SG et al., for the Survival Trial of Antiarrhythmic in Congestive Heart Failure (1995) Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 333: 77–82
Siskind SJ, Sonnenblick EH, Forman J, Scheuer L, Le Jemtel TH (1981) Acute substantial benefit of inotropic therapy with amrinone on exercise hemodynamics and metabolism in severe congestive heart failure. Circulation 64: 966–970
Smith TW, Haber E (1973) Digitalis. Clinical value of the radio-immunoassay of the digitalis glycosides. Pharmacol Rev 25: 219–242
Solomon SD, Jarcho JA, McKenna W et al. (1990) Familiar hypertrophic cardiomyopathy is a genetically heterogenous disease. J Clin Invest 86: 993–999
SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325: 293–302
SOLVD Investigators (1992) Effects of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327: 685–691
Spann JF, Buccino RA, Sonnenblick EH, Braunwaldt E (1967) Contractile state of cardiac muscle obtained from cats with experimentally produced ventricular hypertrophy and heart failure. Circ Res 21: 341–349
Starling EH (1908) The Linacre lecture on the law of the heart. Longmans, London
Starling EH (1921) The law of the heart. Lancet I: 212
Steinfath M, Geertz B, Schmitz Wet al. (1991) Distinct downregulation of cardiac f3,-and ß2-adrenoceptors in different human heart disease. Naunyn Schmiedebergs Arch Pharmacol 343: 217–220
Stoll M, Steckelings UM, Paul M,Bottari SP, Metzger R, Unger R (1995) The angiotensin AT2 receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 95: 651–657
STOP-Hypertension: Dahlöf B, Lindholm LH, Hansson L et al. (1991) Morbidity and mortality in the swedish trial in older patients with hypertension. Lancet 338: 1281–1285
Strauer BE (1976) Änderungen der Kontraktilität bei Druck-and Volumenbelastung des Herzens.Verh Dtsch Ges Kreislaufforsch 42: 69–79
Strauer BE (1979) Das Hochdruckherz. Springer, Berlin Heidelberg New York
Studer R, Reinecke H, Müller B, Holtz J, Just H, Drexler H (1994) Increased Angiotensin-I converting enzyme gene expression in the failing human heart. J Clin Invest 94: 301–310
Sung CP, Arleth A), Ohlstein EH (1993) Carvedilol inhibits vascular smooth muscle cell proliferation. J Cardiovasc Pharm 21: 221–227
Sütsch G, Kiowski W,Yan XW et al. (1998) Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 98: 2262–2268
Suzuki T, Kumazaki T, Mitsiu Y (1993) Endothelin-i is produced and secreted by neonatal rat cardiac myocytes in vitro. Biochem Biophys Res Commun 193: 823–830
Swedberg K, Eneroth P, Kjekshus J,Wilhelmsen L, for the CONSENSUS Trial Study Group (1990) Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 82: 1730–1736
Swedberg K, Held P, Kjekshus J et al., on behalf of the CONSENSUS II Study Group (1992) Effects of the early administration enalapril on mortality in patients with acute myocardial infarction. N Engl J Med 327: 678–684
Swedberg K, Hjalmarson A, Waagstein F, Wallentin I (1979) Prolongation of survival in congestive cardiomyopathy by 3-receptor blockade. Lancet I: 1374–1376
Swedberg K, Viquerat C, Rouleau J-L et al. (1984) Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without failure. Am J Cardiol 54: 783–789
Tada M, Katz AM (1982) Phosphorylation of the sarcoplasmic reticulum and sarcolemma.Annu Rev Physiol 44: 401–423
Takahashi T, Allen P, Lacro R et al. (1992) Expression of dihydropyridine receptor (Ca2’-channel) and calsequestrin genes in the myocardium of patients with end-stage heart failure. J Clin Invest 9o: 927–935
Tan LB, Jalil JE, Pick R, Janicki JS, Weber KT (1991) Cardiac myocyte necrosis induced by angiotensin II. Circ Res 1185–1195
Task Force of the Working Group on Heart Failure of the European Society of Cardiology (1997) The treatment of heart failure. Eur Heart J 18: 736–753
Task Force on Heart Failure of the European Society of Cardiology (1995) Guidelines for the diagnosis of heart failure. Eur Heart J 16: 741–751
Tate CA, Taffet GE, Hudson EK et al. (1990) Enhanced calcium uptake of cardiac sarcoplasmic reticulum in exercise-trained old rats. Am J Physiol 258: H431 - H435
Thomas JA, Marks BH (1978) Plasma norepinephrine in congestive heart failure. Am J Cardiol 41: 233–243
Thomas PB, Eck Liu, Webb ML, Mukherjee R, Spinale FG (1996) Evidence of the endothelin-1 autocrine loop in cardiac myocytes: relation to contractile function with congestive heart failure. Am J Physiol 40: H2629 - H2673
Timmermann PBMWM, Wong PC, Chiu AT et al. (1993) Angiotensin II receptors and angiotensin II receptors antagonists. Pharmacol Rev 45: 205–251
Timsit J, Rion B, Bertherat J et al. (1990) Effects of chronic growth hormone hypersecretion on intrinsic contractility, energetics, isomyosin pattern, and myosin adenosine triphosphatase activity of rat left ventricle. J Clin Invest 86: 507–515
Topol EJ, Traill TA, Fortuin NJ (1985) Hypertensive hypertrophie cardiomyopathy of the elderly. N Engl J Med 312: 277–281
Torre-Amione G, Kapadia S, Lee J et al. (1995) Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation 92: 1487–1493
Torre-Amione G, Kapadia S, Lee J et al. (1996) Tumor necrosis factor-a and tumor necrosis factor receptors in the faiing human heart. Circulation 93: 704–711
Ullrich KJ, Riecker G, Kramer K (1954) Das Druckvolumendia- gramm des Warmblüterherzens. Pflugers Arch 259: 481–489
Unger T, Ganten D, Lang RE, Scholkens VA (1985) Is tissue converting inhibition a determinant of the antihypertensive efficacy of converting enzyme inhibitors? Studies with two different compounds. Hoe 398 and MK 421 in spontaneously hypertensive rats. J Cardiovasc Pharmacol 6: 872–880
Ungerer M, Böhm M, Elce JS, Erdmann E, Lohse MJ (1993) Altered expression of 13-adrenergic receptor kinase and 131-adrenergic receptors in the failing human heart. Circulation 87: 454–463
Unverferth DV, Blanford M, Kates RE, Leier CV (1980) Tolerance to dobutamine after a 72-hour continuous infusion. Am J Med 69: 262–266
Urata H, Nishimura H, Ganten D (1995) Mechanisms of angiotensin II formation in humans. Eur Heart J 16: 79–85
Uretsky BF, Jessup M, Konstam MA et al. (1990) Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Circulation 82: 774–780
Uretsky BF, Young JB, Eden F et al., on behalf of the PROVED Investigate Group (1993) Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: Results of the PROVED Trial. J Am Coll Cardiol 22: 955–962
Van Veldhuisen D, Man A, Dunselman P et al., on behalf of the DIMT Study Group (1993) Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: Results of the Dutch ibopamine multicenter trial ( DIMT ). J Am Coll Cardiol 22: 1564–1573
Vantrimpont P, Rouleau JL, Wun CC et al. (1997) Additive beneficial effects of ß-blockers to angiotensin-converting enzyme inhibitors in the survival and ventricular enlargement (SAVE) study. J Am Coll, Cardiol 29: 229–236
Varonkov Y, Shell WE, Smirnov V, Gukovsky D, Chazov EI (1977) Augmentation of serum CPK activity by digitalis in patients with acute myocardial infarction. Circulation 55: 719–727
Volterrani M, Desenzani P, Lorusso R et al. (1997) Haemodynamic effects of intravenous growth hormone in congestive heart failure. Lancet 349: 1067–1068
Waagstein F, Bristow MR, Swedberg K et al. (1993) Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 342: 1441–1446
Waagstein F, Caidahl K, Wallentin I, Bergh CH, Hjalmarson A (1989) Long-term 13-blockade in dilated cardiomyopathy: effects of short-and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 80: 551–563
Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I (1975) Effect of chronic 3-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 37: 1022–1036
Wada A, Tsutamoto T, Ohnishi M et al. (1999) Effects of a specific endothelin-converting enzyme inhibitor on cardiac, renal, and neurohumoral functions in congestive heart failure. Circulation 99: 570–577
Wankerl M, Böhm M, Morano I et al. (1990) Calcium sensitivity and myosin light chain pattern of atrial and ventricular skinned fibers from patients with various kinds of cardiac disease. J Mol Cell Cardiol 22: 1425–1438
Weber KT, Andrews V, Janicki JS, Likoff M, Reichek N (1982) Pirbuterol, and oral 13-adrenergic receptor agonist in the treatment of chronic cardiac failure. Circulation 66: 1262–1271
Weber KT, Brilla CG (1991) Pathological hypertrophy and cardiac interstitium. Circulation 83: 1849–1865
Weber KT, Brilla CG (1992) Left ventricular hypertrophy and structural remodeling as a determinant of myocardial failure. In: Cruickshank JM, Messerli FH (eds) Left ventricular hypertrophy and its regression. Science, London, pp 21–29
Weinstein LS, Spiegel AM, Carter AD (1988) Cloning and characterization of the human gene of the a-subunit of Gia, a GTPbinding signal transducing protein. FEBS Lett 232: 333–340
Weishaar RE, Kobylarz-Singer DC, Steffen RP, Kaplan HR (1987) Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility. Circ Res 61: 501–509
White HD, Norris RM, Brown MA et al. (1987) Left ventricular endsystolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 76: 44–51
WHO (1995) Physician guidelines (for GPS) designed to be transla- ted and distributed worldwide to primary care physicans.
Wikstrand J, Kendall M (1992) The role of b receptor blockade in preventing sudden death. Eur Heart J 13: 111–120
Wilmshurst PT, Thompson DS, Jenkins BS et aL (1983) Haemodynamic effects of intravenous amrinone in patients with impaired left ventricular function. Br Heart J 49: 77–82
Wilson JR, Mancini DM (1993) Skeletal muscle metabolic dysfunction–implications for exercise intolerance in heart failure. Circulation 82 (Suppl VII): 104–109
Wilson JR, Reichek JR, Dunkman WB, Goldberg S (1981) Effect of diuresis on the performance of the failing left ventricle in man. Am J Med 7o: 234–239
Woodley SL, Gilbert EM, Anderson JL et al. (1991) 13-blockade with bucindolol in heart failure caused by ischemic vs. idiopathic dilated cardio-myopathy. Circulation 84: 2426–2441
XAMOTEROL in severe heart failure study group (1990) Xamoterol severe heart failure. Lancet 336: 1–6
Xiao RP, Spurgeon HA, O’Connor F, Lakatta EG (1994) Age-associated changes in 3-adrenergic modulation on rat cardiac excitation-contraction coupling. J Clin Invest 94: 2051–2059
Xu D, Emoto N Giaid A, Slaughter C et al. (1994) ECE-1: A membrane bound metalloprotease that catalyzes the proteolytic activation of big endothelin-i. Cell 78: 473–485
Yamada H, Fabris B, Allen AM (1991) Localization of angiotensin converting enzyme in rat heart. Circ Res 68: 141–151
Yamada T, Horiuchi M, Dzau VJ (1996) Angiotensin II type 2 receptors mediates programmed cell death. Proc Natl Acad Sci USA 93: 150–160
Yonezawa T, Umemoto S, Fujii A, Katayama K, Matsuzaki (1996) Comparative effects of type 1 angiotensin II-receptor blockade with angiotensin-converting-enzyme inhibitor of left ventricular distensibility and collagen metabolism in spontaneously hypertensive rats. J of Cardiovasc Pharmacol 27: 119–124
Yue TL, McKenna PG, Gu JL et al. (1994) Carvedilol, a new vasodilatating ß-adrenoceptor blocker antihypertensive drug, protects endothelial cells from damage initiated by xanthine-xanthine oxidase and neutrophils. Cardiovasc Res 28: 400–406
Yue TL, McKenna PJ, Gu JL, Cheng HY, Ruffolo RR, Feuerstein GZ (1993) Carvedilol, a new antihypertensive agent, prevents lipid peroxidation and oxidative injury to endothelial cells. Hypertension 22: 922–928
Zierhut W, Stude R, Laurent D et al. (1996) Left ventricular wall stress and sarcoplasmic reticulum Cat+-ATPase gene expression in renal hypertensive rats: dose-dependent effects of ACE inhibition and AT1-receptor blockade. Cardiovasc Res 31: 758–768
Zolk O, Quattek MS, Sitzler G et al. (1999) Expression of endothelin-1, endothelin converting enzyme, and endothelin-receptors in chronic heart failure. Circulation 99: 2218–2123
Zucker IH, Earle AM, Gilmore JP (1977) The mechanism of adaptation of left atrial stretch receptors in dogs with chronic congestive heart failure. J Clin Invest 60: 323–331
Zucker IH, Wang W, Chen J-S (1990) Baroreceptor and cardiac receptor abnormalities in experimental heart failure. Heart Failure 6: 33–41
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Beuckelmann, D.J. (2000). Akute kardiale Dyspnoe und Lungenödem. In: Erdmann, E. (eds) Klinische Kardiologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-12156-6_27
Download citation
DOI: https://doi.org/10.1007/978-3-662-12156-6_27
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-12157-3
Online ISBN: 978-3-662-12156-6
eBook Packages: Springer Book Archive